U-PLEX Immuno-Oncology Group 1 (human) 107-Plex

Click image to enlarge

The U-PLEX Immuno-Oncology Group 1 (human) 107-Plex is a panel of biomarkers (Table 1) that has been tested for multiplex compatibility and is fulfilled as a kit. The U-PLEX Immuno-Oncology Group 1 (human) 107-Plex contains biomarkers related to Immuno-Oncology. It is a mix of inflammatory biomarkers, metabolic markers, and emerging biomarkers in Immuno-Oncology. The U-PLEX Immuno-Oncology Group 1 (human) 107-Plex can be used for quantitative measurements in serum and plasma, and offers detection limits (LLODs) in the sub- to low pg/mL range. Custom subplexes of this panel can be easily created online using MSD’s U-PLEX Assay Designer.

Table 1. List of analytes and typical detection limits

Analyte	LLOD - ULOD	Unit
BAFF-R/TNFRSF13C	1.4 - 14,000	pg/mL
BCMA/TNFRSF17	0.13 - 600	pg/mL
CD20	5.7 - 80,000	pg/mL
CD27	0.41 - 3,400	pg/mL
CD276/B7-H3	4.0 - 40,000	pg/mL
CD28	14 - 144,000	pg/mL
CD40L (soluble)	0.23 - 1,800	pg/mL
C-Peptide	14 - 7,610	pg/mL
CTACK	1.8 - 4,200	pg/mL
CTLA-4	0.12 - 1500	pg/mL
ENA-78	0.53 - 3,940	pg/mL
Eotaxin	3.2 - 4,840	pg/mL
Eotaxin-2	3.1 - 6,000	pg/mL
Eotaxin-3	7.3 - 21,400	pg/mL
EPO	1.8 - 20,000	pg/mL
FGF (basic)	2.1 - 1,200	pg/mL
FGF-23	0.75 - 3,000	pg/mL
FLT3L	0.49 - 6,000	pg/mL
Fractalkine	100 - 181,000	pg/mL
FSH	9.0 - 75,000	µIU/mL
G-CSF	1.6 - 20,400	pg/mL
Ghrelin (active)	13 - 7,160	pg/mL
GIP (active)	1.3 - 1,920	pg/mL
GIP (inactive)	27 - 12,500	pg/mL
GITR/TNFRSF18	0.18 - 1,300	pg/mL
GITRL/TNFSF18	0.09 - 1,000	pg/mL
GLP-1 (active)	0.01 - 57	pM
GLP-1 (inactive)	1.5 - 576	pM
GM-CSF	0.12 - 9,440	pg/mL
gp130 (soluble)	5.8 - 188,000	pg/mL
Granzyme A	0.49 - 3,700	pg/mL
Granzyme B	0.10 - 750	pg/mL
GRO-α	0.25 - 2,500	pg/mL
HAVCR2/TIM-3	2.1 - 9,500	pg/mL
I-309	6.8 - 3,000	pg/mL
IFN-α2a	4.0 - 42,400	pg/mL
IFN-β	3.1 - 100,000	pg/mL
IFN-γ	1.7 - 17,000	pg/mL
IL-1α	0.98 - 5,080	pg/mL
IL-1β	0.15 - 3,820	pg/mL
IL-1RA	1.7 - 5,000	pg/mL
IL-2	0.70 - 1,940	pg/mL
IL-2Rα	10 - 55,000	pg/mL
IL-3	11 - 16,000	pg/mL
IL-4	0.08 - 2,060	pg/mL
IL-5	0.24 - 4,040	pg/mL
IL-6	0.33 - 1,980	pg/mL
IL-7	1.5 - 7,040	pg/mL
IL-8	0.15 - 2,210	pg/mL
IL-9	0.14 - 1,500	pg/mL
IL-10	0.14 - 3,720	pg/mL
IL-12/IL-23p40	2.8 - 21,000	pg/mL

Analyte	LLOD - ULOD	Unit
IL-12p70	0.69 - 5,320	pg/mL
IL-13	3.1 - 1,920	pg/mL
IL-15	0.82 - 3,030	pg/mL
IL-16	6.6 - 21,500	pg/mL
IL-17A	2.6 - 23,400	pg/mL
IL-17A/F	1.8 - 18,400	pg/mL
IL-17C	2.2 - 20,000	pg/mL
IL-17D	4.8 - 40,000	pg/mL
IL-17E/IL-25	0.58 - 9,240	pg/mL
IL-17F	160 - 112,000	pg/mL
IL-18	2.5 - 42,000	pg/mL
IL-21	1.2 - 12,600	pg/mL
IL-22	0.13 - 3,420	pg/mL
IL-23	1.4 - 21,600	pg/mL
IL-27	9.6 - 50,600	pg/mL
IL-29/IFN-λ1	1.2 - 11,820	pg/mL
IL-31	7.3 - 11,100	pg/mL
IL-33	0.59 - 10,300	pg/mL
Insulin	0.32 - 736	µIU/mL
IP-10	0.49 - 6,000	pg/mL
I-TAC	1.5 - 5,080	pg/mL
LAG3	6.8 - 36,000	pg/mL
Leptin	14 - 47,500	pg/mL
LH	0.05 - 130	pM
MCP-1	0.74 - 6,560	pg/mL
MCP-2	0.11 - 2,000	pg/mL
MCP-4	7.5 - 3,800	pg/mL
M-CSF	0.29 - 2,000	pg/mL
MDC	8.4 - 20,100	pg/mL
MIF	4.3 - 27,000	pg/mL
MIP-1α	7.7 - 4,200	pg/mL
MIP-1β	1.5 - 1,640	pg/mL
MIP-5	0.34 - 30,000	pg/mL
OX40/TNFRSF4	0.26 - 1,800	pg/mL
PD1 (epitope 1)	0.25 - 2,200	pg/mL
PD1 (epitope 2)	0.11 - 2,200	pg/mL
PD-L1 (epitope 1)	0.09 - 1,100	pg/mL
PD-L2	3.9 - 41,000	pg/mL
PlGF	0.19 - 1,200	pg/mL
PP	0.19 - 1,830	pg/mL
Proinsulin	0.05 - 130	pM
PYY (total)	2.7 - 2,260	pg/mL
RANKL/TNFSF11	1.8 - 4,000	pg/mL
SDF-1α	280 - 103,000	pg/mL
Tie-2	2.9 - 29,000	pg/mL
TIGIT	0.36 - 3,500	pg/mL
TLR1	4.4 - 37,000	pg/mL
TNF-α	0.51 - 3,650	pg/mL
TNF-β	0.47 - 4,320	pg/mL
TPO	19 - 40,400	pg/mL
TRAIL	0.66 - 10,000	pg/mL
TSLP	0.20 - 10,100	pg/mL
VEGF-A	2.0 - 4,920	pg/mL
VEGF-D	0.30 - 1,500	pg/mL
YKL-40	0.39 - 5,000	pg/mL

Specifications
Documentation
References

Application(s)		Immunology/Inflammation
Analyte(s)		BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, C-Peptide, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF (basic), FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (active), GIP (active), GIP (inactive), GITR/TNFRSF18, GITRL/TNFSF18, GLP-1 (active), GLP-1 (inactive), GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, I-TAC, LAG3, Leptin, Luteinizing Hormone (LH), MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L2, PlGF, PP, Proinsulin, PYY (total), RANKL/TNFSF11, SDF-1α, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, YKL-40
Species		Human
Instrument(s)		SECTOR Imager 2400 , MESO QuickPlex SQ 120MM , MESO SECTOR S 600 , SECTOR Imager 6000 , MESO SECTOR S 600MM , MESO QuickPlex SQ 120
U-PLEX Group Compatibility		Immuno-Oncology Group 1
Plate Type		96-well
Sample Type		Plasma, Serum
Usage Statement		For Research Use Only. Not for use in diagnostic procedures.
Storage Statement(s)		Please refer to the product insert for the storage conditions of individual kit components.
Storage Condition		Multi-Component
Schedule B Code		3822.19.0000

Contact Information

Customer Service/Orders
1-240-314-2795

5:00 a.m. to 8:00 p.m.
US Eastern Time

Email

Scientific/Technical Support
1-240-314-2798

5:30 a.m. to 5:30 p.m.
US Eastern Time

Email

Instrument Support
1-301-947-2057

8:30 a.m. - 5:30 p.m.
US Eastern Time

Email

Company Headquarters
1-240-314-2600
1601 Research Blvd.
Rockville, Maryland 20850-3173
USA

Product Inserts		U-PLEX Immmuno-Oncology Group 1 human Multiplex Insert
Datasheets		IL-25 U-PLEX Human BAFF-R/TNFRSF13C U-PLEX Human BCMA/TNFRSF17 U-PLEX Human CD20 U-PLEX Human CD27 U-PLEX Human CD276/B7-H3 U-PLEX Human CD28 View More
Product Highlights		U-PLEX Platform Highlights
SDS		Biotin-conjugated Antibodies Safety Data Sheet Diluent 2, Diluent 3, Diluent 5, Diluent 7 and Diluent 8 Diluent 50, Diluent 56, Diluent 61, Diluent 100, and Diluent 101 Diluent 57, Diluent 58, and Diluent 59 MSD Calibrators and Controls MSD GOLD Read Buffer B U-PLEX Linker Set

Title	Journal	Year
Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops Ilaria Marzinotto, David L Pittman, Alistair J K Williams, Anna E Long, Peter Achenbach, Michael Schlosser, Beena Akolkar, William E Winter, Vito Lampasona; participating laboratories	Diabetologia	2023
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke Fiona Chapman, Sarah Jean Pour, Roman Wieczorek, Edgar Trelles Sticken, Jessica Budde, Karin Röwer, Sandra Otte, Elizabeth Mason, Lukasz Czekala, Thomas Nahde, Grant O’Connell, Liam Simms and Matthew Stevenson	Frontiers in Toxicology	2023
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma Paolo Strati, Andrew Jallouk, Qing Deng, Xubin Li, Lei Feng, Ryan Sun, Sherry Adkins, Swapna Johncy, Taylor Cain, Raphael E. Steiner, Sairah Ahmed, Dai Chihara, Luis E. Fayad, Swaminathan P. Iyer, Sandra Horowitz, Loretta J. Nastoupil, Ranjit Nair, Ahmed Hassan, Taher E. Daoud, Misha Hawkins, Maria A. Rodriguez, Elizabeth J. Shpall, Jeremy L. Ramdial, Partow Kebriaei, David S. Hong, Jason R. Westin, Sattva S. Neelapu, Michael R. Green	Blood Advances	2023
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms Arvid Edén, Anna Grahn, Daniel Bremell, Anahit Aghvanyan, Pradeepthi Bathala, Dietmar Fuchs, Johanna Gostner, Lars Hagberg, Nelly Kanberg, Sunsanee Kanjananimmanont, Magnus Lindh, Salvia Misaghian, Staffan Nilsson, Michael Schöll, George Sigal, Erika Stentoft, Marie Studahl, Aylin Yilmaz, Mingyue Wang, Martin Stengelin, Henrik Zetterberg, Magnus Gisslén	JAMA Network Open	2022
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations Bing Sun, Norina Tang, Michael J. Peluso, Nikita S. Iyer, Leonel Torres, Joanna L. Donatelli, Sadie E. Munter, Christopher C. Nixon, Rachel L. Rutishauser, Isabel Rodriguez-Barraquer, Bryan Greenhouse, John D. Kelly, Jeffrey N. Martin, Steven G. Deeks, Timothy J. Henrich, and Lynn Pulliam	Cells	2021
View All

Please Sign In

User name

Password

U-PLEX Immuno-Oncology Group 1 (human) 107-Plex

Top Products

Contact Information

Products

Services

Orders & Support

Key Topics